DDInter1127 DDInter131
Measles virus vaccine live attenuated is a live virus vaccine for simultaneous vaccination against measles, which is a common childhood disease. The vaccine is prepared from the attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture.
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Measles virus vaccine live attenuated {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Measles virus vaccine live attenuated {u} may lead to a major life threatening interaction when taken with {v} Talazoparib
Measles virus vaccine live attenuated {u} may lead to a major life threatening interaction when taken with {v} Tositumomab
Measles virus vaccine live attenuated may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Talazoparib
Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Tositumomab